Horizon Therapeutics Ireland DAC

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Activity

Key Events

Oct 10, 2025FDAOlpruva — OLPRUVA

Nov 22, 2022TrialStudy to Evaluate HZN-457 in Healthy Volunteers

Jun 17, 2022FDAOlpruva — PHEBURANE

Jun 11, 2020FDAUPLIZNA — UPLIZNA

Feb 14, 2020FDAProcysbi — PROCYSBI

Jan 21, 2020FDATEPEZZA — TEPEZZA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

8 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Procysbi11 patentsJan 26, 2027 ProcysbiMar 22, 2028 Ravicti14 patentsSep 22, 2030 RavictiMar 9, 2032 Procysbi4 patentsJun 17, 2034 Procysbi4 patentsAug 16, 2036 Olpruva3 patentsOct 17, 2036 Procysbi4 patentsFeb 16, 2037

Regulatory

Regulatory Timeline

19941 event

FDAAug 15

Procysbi — CYSTAGON

Application NDA020392 (NDA)

19962 events

FDAMay 13

Olpruva — BUPHENYL

Application NDA020572 (NDA)

FDAApr 30

Olpruva — BUPHENYL

Application NDA020573 (NDA)

19991 event

FDAFeb 25

Actimmune — ACTIMMUNE

Application BLA103836 (BLA)

20101 event

FDASep 14

KRYSTEXXA — KRYSTEXXA

Application BLA125293 (BLA)

20132 events

FDAApr 30

Procysbi — PROCYSBI

Application NDA203389 (NDA)

FDAFeb 1

Ravicti — RAVICTI

Application NDA203284 (NDA)

20203 events

FDAJun 11

UPLIZNA — UPLIZNA

Application BLA761142 (BLA)

FDAFeb 14

Procysbi — PROCYSBI

Application NDA213491 (NDA)

FDAJan 21

TEPEZZA — TEPEZZA

Application BLA761143 (BLA)

20221 event

FDAJun 17

Olpruva — PHEBURANE

Application NDA216513 (NDA)

20251 event

FDAOct 10

Olpruva — OLPRUVA

Application NDA214860 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)